Dr. Jeffrey R. Jay, M.D.
Latest statistics and disclosures from Great Point Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, VOR, IBRX, VERA, ZURA, and represent 35.67% of Great Point Partners's stock portfolio.
- Added to shares of these 10 stocks: ABVX (+$81M), RARE (+$20M), DFTX (+$20M), VERA (+$17M), SGMT (+$16M), IMMX (+$9.6M), MLTX (+$6.9M), IFRX (+$6.8M), IRD (+$6.8M), ANNX (+$5.7M).
- Started 12 new stock positions in ALT, Scynexis, Amanat Acquisition Corp, ELVN, ABVX, RNTX, DBVT, IFRX, SGMT, DFTX. Jatt Ii Acquisition Corp, RARE.
- Reduced shares in these 10 stocks: APGE (-$32M), AMLX (-$19M), Kalvista Pharmaceuticals (-$14M), IMVT (-$14M), JBIO (-$14M), ZBIO (-$10M), NKTR (-$9.9M), DRUG (-$7.7M), CMPX (-$7.1M), SCYX (-$6.9M).
- Sold out of its positions in JBIO, APGE, AVTX, CMPX, CNTX, IMVT, Kalvista Pharmaceuticals, SCYX, TENX, UNCY. ZBIO, ALKS, PHVS.
- Great Point Partners was a net buyer of stock by $43M.
- Great Point Partners has $529M in assets under management (AUM), dropping by 21.60%.
- Central Index Key (CIK): 0001281446
Tip: Access up to 7 years of quarterly data
Positions held by Dr. Jeffrey R. Jay, M.D. consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Great Point Partners
Great Point Partners holds 41 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax Sa Sponsored Ads (ABVX) | 15.2 | $81M | NEW | 604k | 133.26 |
|
| Vor Biopharma Com New (VOR) | 5.9 | $31M | -2% | 1.7M | 18.41 |
|
| Immunitybio Put Option (IBRX) | 5.0 | $26M | 3.0M | 8.76 |
|
|
| Vera Therapeutics Cl A (VERA) | 4.9 | $26M | +201% | 601k | 42.91 |
|
| Zura Bio Class A Ord Shs (ZURA) | 4.7 | $25M | 4.2M | 5.90 |
|
|
| Alumis (ALMS) | 4.6 | $24M | 856k | 28.14 |
|
|
| Sol-gel Technologies Shs New (SLGL) | 3.8 | $20M | 274k | 74.14 |
|
|
| Ultragenyx Pharmaceutical Put Option (RARE) | 3.8 | $20M | NEW | 600k | 33.39 |
|
| Definium Therapeutics Com Shs (DFTX) | 3.8 | $20M | NEW | 425k | 47.04 |
|
| Annexon (ANNX) | 3.8 | $20M | +40% | 3.5M | 5.71 |
|
| Oruka Therapeutics (ORKA) | 3.3 | $17M | 183k | 95.17 |
|
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 3.1 | $17M | +71% | 856k | 19.47 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 3.0 | $16M | NEW | 2.0M | 7.73 |
|
| Contineum Therapeutics Cl A (CTNM) | 2.9 | $15M | +15% | 922k | 16.39 |
|
| Immix Biopharma (IMMX) | 2.5 | $13M | +265% | 1.3M | 10.31 |
|
| Eliem Therapeutics (CLYM) | 2.5 | $13M | -25% | 1.0M | 13.04 |
|
| Amylyx Pharmaceuticals (AMLX) | 2.4 | $13M | -60% | 700k | 17.96 |
|
| Nektar Therapeutics Com New (NKTR) | 2.3 | $12M | -44% | 175k | 69.81 |
|
| Neurogene (NGNE) | 2.1 | $11M | -29% | 352k | 31.45 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 1.9 | $10M | +5% | 317k | 32.45 |
|
| Ocuphire Pharma (IRD) | 1.5 | $8.1M | +507% | 2.0M | 4.11 |
|
| Eupraxia Pharmaceuticals (EPRX) | 1.5 | $7.9M | 1.2M | 6.61 |
|
|
| Bright Minds Biosciences Com New (DRUG) | 1.5 | $7.7M | -50% | 110k | 70.20 |
|
| Inflarx Nv (IFRX) | 1.3 | $6.8M | NEW | 3.0M | 2.24 |
|
| Relmada Therapeutics (RLMD) | 1.1 | $5.8M | 842k | 6.92 |
|
|
| Jatt Ii Acquisition Corp Ord Shs | 1.1 | $5.7M | NEW | 500k | 11.36 |
|
| Cullinan Oncology (CGEM) | 1.0 | $5.5M | 300k | 18.21 |
|
|
| Altimmune Com New (ALT) | 1.0 | $5.3M | NEW | 1.7M | 3.04 |
|
| Amanat Acquisition Corp Cl A Ord | 1.0 | $5.1M | NEW | 500k | 10.16 |
|
| Rezolute Com New (RZLT) | 0.9 | $4.9M | 952k | 5.20 |
|
|
| Silence Therapeutics Ads (SLN) | 0.9 | $4.9M | -55% | 450k | 10.98 |
|
| Palisade Bio (PALI) | 0.9 | $4.8M | -32% | 2.3M | 2.09 |
|
| Evommune Com Shs (EVMN) | 0.8 | $4.3M | 325k | 13.29 |
|
|
| Scynexis | 0.7 | $3.8M | NEW | 944k | 4.07 |
|
| Galectin Therapeutics Com New Call Option (GALT) | 0.7 | $3.7M | 800k | 4.64 |
|
|
| Enliven Therapeutics (ELVN) | 0.7 | $3.6M | NEW | 70k | 50.75 |
|
| Humacyte (HUMA) | 0.6 | $2.9M | 3.8M | 0.78 |
|
|
| Rein Therapeutics Com New (RNTX) | 0.5 | $2.7M | NEW | 2.6M | 1.04 |
|
| Dbv Technologies S A Sponsored Ads (DBVT) | 0.5 | $2.6M | NEW | 157k | 16.40 |
|
| Anavex Life Sciences Corp Com New Call Option (AVXL) | 0.3 | $1.4M | 521k | 2.59 |
|
|
| Promis Neurosciences Com Shs (PMN) | 0.2 | $1.1M | -76% | 86k | 13.16 |
|
Past Filings by Great Point Partners
SEC 13F filings are viewable for Great Point Partners going back to 2013
- Great Point Partners 2026 Q2 filed Aug. 14, 2026
- Great Point Partners 2026 Q1 filed May 15, 2026
- Great Point Partners 2025 Q4 filed Feb. 17, 2026
- Great Point Partners 2025 Q3 filed Nov. 14, 2025
- Great Point Partners 2025 Q2 filed Aug. 14, 2025
- Great Point Partners 2025 Q1 filed May 15, 2025
- Great Point Partners 2024 Q4 filed Feb. 14, 2025
- Great Point Partners 2024 Q3 filed Nov. 13, 2024
- Great Point Partners 2024 Q2 filed Aug. 14, 2024
- Great Point Partners 2024 Q1 filed May 15, 2024
- Great Point Partners 2023 Q4 filed Feb. 14, 2024
- Great Point Partners 2023 Q3 filed Nov. 14, 2023
- Great Point Partners 2023 Q2 filed Aug. 14, 2023
- Great Point Partners 2023 Q1 filed May 15, 2023
- Great Point Partners 2022 Q4 filed Feb. 14, 2023
- Great Point Partners 2022 Q3 filed Nov. 14, 2022